secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106944
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q2 operating expenses $9M; FDA clears IND path for (Z)-endoxifen in metastatic breast cancer
--------------------------------------------------------------------------------

- Total operating expenses $9.0M in Q2 2025, up 27% YoY from $7.1M; R&D spend rose 55% to $5.5M.
- FDA feedback July 2025: no additional toxicity studies needed; Atossa plans IND submission in Q4 2025 for (Z)-endoxifen in metastatic breast cancer.
- I-SPY2 pilot (20 patients): 95% completed ≥75% dosing; median Ki-67 dropped from 10.5% to 5%; functional tumor volume decreased 77.7% by MRI.
- Issued U.S. Patent 12,281,056 with 58 claims covering (Z)-endoxifen enteric formulations; two other patents under post-grant challenge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025106944/0000950170-25-106944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025106944/atos-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer